GlassScriptPhysician profile
Shuo S Zhou
NPI 1184099954
$18,322.26
in general payments reported to CMS, 2019-2025
60 companies · $1,406 in 2025
The $1,406 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,399 · 2020: $988 · 2021: $1,934 · 2022: $3,747 · 2023: $3,369 · 2024: $2,479 · 2025: $1,406.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,253.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,564.36 | 2019-2025 | Repatha, Krystexxa, Otezla |
| Abbvie INC. | $2,160.45 | 2019-2025 | Linzess, Viberzi, Creon |
| Astrazeneca Pharmaceuticals LP | $1,745.58 | 2019-2025 | Farxiga, Lokelma, Breztri |
| Horizon Therapeutics Plc | $1,067.40 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $834.83 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $778.59 | 2021-2025 | |
| Lilly USA, LLC | $757.21 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $751.47 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.65 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $492.47 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Sumitomo Pharma America, INC. | $487.61 | 2023-2025 | Gemtesa |
| Gilead Sciences, INC. | $453.35 | 2019-2025 | |
| Radius Health, INC. | $381.82 | 2019-2025 | Tymlos |
| Novartis Pharmaceuticals Corporation | $365.55 | 2019-2025 | |
| Pfizer INC. | $363.96 | 2019-2024 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuo Zhou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.